5. Casos De SAF

See our User Agreement and Privacy Policy. See our Privacy Policy and User Agreement for details.

403 Forbidden

Published on Jun 1, Sindrome antifosfolipidico SAF Generalidades. Clipping is a handy way to collect and organize the most important slides from a presentation.

You can keep your great finds in clipboards organized around topics. SlideShare Explore Search You. Successfully SAF this 5. Casos. We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads.

You can change your ad preferences anytime. AI and Machine Learning Demystified Show related SlideShares at end.

Full Name Comment goes here. Are you sure you want to Yes No. Embeds 0 No embeds. No notes for slide.

Dia da Prevenção da Síndrome Alcoólica Fetal ou SAF (17 de julho)

SAF Sindrome antifosfolipidico saf 1. We review the published scientific evidence on the use of rituximab in the treatment 5. Casos primary APS. Description of a case and review of the literature with descriptive analysis of the demographic, clinical, and immunologic features, treatment and outcome of patients.

We identified 24 patients 15 women [ The reasons for the use of rituximab were thrombocytopenia Lupus anticoagulant was present in Four patients with clinical improvement presented with aPL titer decrease and in one patient, aPL levels did not change. In one patient without clinical response, aPL remained positive. A clinical-immunologic dissociation existed in 2 additional cases.

Tema A propósito de un caso de SAF

The results obtained suggest a possible potential benefit of rituximab in the treatment of some clinical manifestations of primary APS such as thrombocytopenia, skin and heart valve involvement. Patients and methods Description of a case and review of the literature with descriptive analysis of the demographic, clinical, and immunologic features, treatment and outcome of patients.

Results We identified 24 patients 15 women [

2 Comentário

  1. Maria Laura:

    Full Name Comment goes here.

  2. Bruno:

    Patients without another associated autoimmune disease are considered to have primary APS.